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A 42-year-old man was referred for the evaluation of diffuse
bone pain and newly found hypophosphatemia. He had
progressive bone pain over the lower back, pelvis, and
bilateral hips, muscle weakness and difficult ambulation since
3 years ago. Initially, he was diagnosed to have ankylosing
spondylitis but failed to respond with non-steroidal anti-
inflammatory drugs, etoxicomab and etanercept therapy. One
month ago, he was admitted at orthopedic ward for L-spine
compression fracture. Radiography revealed a Looser zone at
right proximal femur. 99mTc-bone scintigraphy showed
diffuse skeletal uptake including axial bone, ribs, and
proximal femurs. The detailed searches including computed
tomography of the chest and abdomen, immune disorders,
and malignancy were unrevealing. The pertinent laboratory
results are shown in Table 1. He was put on oral calcitriol
2 mg and phosphorous salt containing phosphate 2 g daily.
Nevertheless, his hypophosphatemia persisted and diffuse
bone pain was only partially alleviated.
On physical examination, he was a well-nourished
kyphotic man with waddling gait and severe pain on any
movement. Of note, a 2 3 cm elastic mass in the instep of
left foot was identified (Figure 1).
What is the cause of his unexplained bone pain?
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Table 1 | Laboratory results
Unit Reference
Serum
Blood urea nitrogen mmol/l 2.0–7.2 3.7
Creatinine mmol/l 26.5–114.9 61.9
Calcium mmol/l 2.0–2.5 2.15
Phosphate mmol/l 0.87–1.52 0.65
Albumin g/l 35–50 42
Alkaline phosphatase mkat/l 0.13–2.10 6.1
iPTH pg/ml 12–72 216
25(OH) vitD3 nmol/l 24.2–103.8 43.8
1.25(OH)2 vitD3 pmol/l 38.2–133.4 66.7
24-h urine
Calcium mmol 1.25–6.25 0.81
Phosphate mmol 12.8–41.6 43.9
Creatinine mmol 7.1–16.0 15.7
Abbreviations: iPTH, immunoreactive parathyroid hormone; vitD3, vitamin D3.
Figure 1 |Photograph of the soft tissue mass at the instep of
left foot.
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The Diagnosis | Oncogenic osteomalacia
His bone pain, atraumatic fracture, Looser fracture at radio-
graphy and hypophosphatemia associated with elevated alkaline
phosphatase were consistent with osteomalacia. His hypopho-
sphatemia with high urinary phosphate excretion indicated renal
hypophosphatemia. The causes of severe hypophosphatemia
associated with hyperphosphaturia are shown in Table 2. His
normocalcemia, inappropriately low serum calcitriol in response
to hypophosphatemia, and high serum fibroblast growth factor-
23 (FGF23, 187.5pg/ml, reference 10–50) suggested the FGF23
associated causes. His negative family history, adult-onset, and
identification of a soft tissue mass imply tumor-induced
osteomalacia but not hereditary hypophosphatemic disorders.
Complete tumor resection showed phosphaturic mesenchymal
tumor, mixed connective tissue type (Figure 2). His serum
FGF23 was 14.3pg/ml, immunoreactive parathyroid hormone
65pg/ml, and calcitriol 146.2 pmol/l 2 days after operation.
Delayed normalization of serum phosphate level, was found
because phosphate deposited into bone soon after operation, like
hungry bone syndrome. Without phosphate supplement, his
clinical symptoms completely resolved in 3 months.
Tumor-induced osteomalacia or oncogenic osteomalacia is
a rare paraneoplastic syndrome characterized by tumor-
induced renal phosphate wasting with hypophosphatemia
and defective calcitriol metabolism. It is perhaps the most
common cause of adult-onset hyperphosphaturic osteoma-
lacia and usually caused by benign mesenchymal tumors that
secret phosphatonins, primarily FGF23.1 Circulating FGF23
binds with a complex of klotho and FGF23 receptor at
proximal tubules to suppress both the expression of NaPi-2a/2c
and 1a-hydroxylase, causing renal phosphate wasting
and inappropriately low to normal serum calcitriol.2,3
Secondary hyperparathyroidism is likely a compensatory
response to maintain normocalcemia, whereas calcitriol is
suppressed.4
Treatment of tumor-induced osteomalacia relies on early
recognition, localization, and surgical removal of tumor.
Tumor-induced osteomalacia is frequently misdiagnosed
because clinical symptoms are often insidious and non-
specific diffuse bone pain, muscle weakness, and atraumatic
fracture. Without timely measurement of serum phosphate,
the time from onset of symptoms to diagnosis is usually
delayed, over 2–4 years. Once recognized, tumor localization
is the key despite its small size and slow progression.1 Many
culprit tumors are found in soft tissues and bone in the
extremities and craniofacial regions.4,5 Special attention to
these sites is important to avoid futile examinations. Selective
venous sampling for FGF23, whole-body computed tomo-
graphy/magnetic resonance imaging, positron-emission to-
mography and octreotide-labeled scintigram may aid
localizing clinically occult tumor.1,3–5 Complete cure can be
achieved only by the surgical removal of offending tumor.
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Table 2 | The common causes of severe hypophosphatemia with hyperphosphaturia
Hypercalcemia (increased serum PTH or PTHrP) Normocalcemia (isolated renal phosphate wasting) Hypocalcemia (tubulopathy)
Increased urine Ca2+ excretion Increased serum FGF23 level Fanconi syndrome
Primary or post-renal transplant hyperparathyroidism XLHR (PHEX mutation) Renal tubular acidosis
Paraneoplastic syndrome with elevated PTHrP ADHR (FGF23 mutation), ARHR (DMP-1 mutation) Bartter’s-like syndrome
Reduced urine Ca2+ excretion (CaSR loss of function) Tumor-induced osteomalacia (acquired)
Familial hypocalciuric hypercalcemia Decreased serum FGF23 level
Neonatal severe hyperparathyroidism HHRH (NaPi IIa or IIc mutation)
Abbreviations: ADHR, autosomal dominant hypophosphatemic rickets; ARHR, autosomal recessive hypophosphatemic rickets; CaSR, calcium-sensing receptor; DMP-1, dentin
matrix protein 1; FGF, fibroblast growth factor; HHRH, hereditary hypophosphatemic rickets with hypercalciuria; PHEX, phosphate regulating gene with homologies to
endopeptidase on the X chromosome; PTHrP, parathyroid hormone related peptide; XLHR, X-linked hypophosphatemic rickets.
Figure 2 |Hematoxylin and Eosin staining (100) showing
phosphaturic mesenchymal tumor, mixed connective tissue type
consisting of vascular, chondroid, muscular, and adipose tissue.
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